Literature DB >> 6168775

Monoclonal antibodies to two glycoproteins of herpes simplex virus type 2.

N Balachandran, D Harnish, R A Killington, S Bacchetti, W E Rawls.   

Abstract

Monoclonal antibodies to herpes simplex virus type 2 were found to precipitate different numbers of radiolabeled polypeptides from lysates of virus-infected cells. Antibodies directed against two viral glycoproteins were characterized. Antibodies from hybridoma 17 alpha A2 precipitated a 60,000-molecular-weight polypeptide which chased into a 66,000- and 79,000-molecular-weight polypeptide. All three polypeptides labeled in the presence of [3H]glucosamine and had similar tryptic digest maps. The 60,000-molecular-weight polypeptide also chased into a 31,000-molecular-weight species which did not label with [3H]glucosamine. Antibodies from hybridoma 17 beta C2 precipitated a 50,000-molecular-weight polypeptide which chased into a 56,000- and 80,000-molecular weight polypeptide. These polypeptides also shared a similar tryptic digest map and labeled with [3H]glucosamine. Both monoclonal antibodies were herpes simplex virus type 2 specific. The viral proteins precipitated by 17 alpha A2 antibodies had characteristics similar to those reported for glycoprotein E, whereas the proteins precipitated by 17 beta C2 antibodies appeared to represent a glycoprotein not previously described. This glycoprotein should be tentatively designated glycoprotein F.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168775      PMCID: PMC171353          DOI: 10.1128/JVI.39.2.438-446.1981

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Deoxypyrimidine kinases of herpes simplex viruses types 1 and 2: comparison of serological and structural properties.

Authors:  M E Thouless; P Wildy
Journal:  J Gen Virol       Date:  1975-02       Impact factor: 3.891

2.  Polypeptide synthesized in herpes simplex virus type 2-infected HEp-2 cells.

Authors:  K L Powell; R J Courtney
Journal:  Virology       Date:  1975-07       Impact factor: 3.616

3.  Site of synthesis of membrane and nonmembrane proteins of vesicular stomatitis virus.

Authors:  T G Morrison
Journal:  J Biol Chem       Date:  1975-09-10       Impact factor: 5.157

4.  Proteins specified by herpes simplex virus. XI. Identification and relative molar rates of synthesis of structural and nonstructural herpes virus polypeptides in the infected cell.

Authors:  R W Honess; B Roizman
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

5.  Isolation and characterization of a large molecular-weight polypeptide of herpes simplex virus type 1.

Authors:  R J Courtney; M Benyesh-Melnick
Journal:  Virology       Date:  1974-12       Impact factor: 3.616

6.  Proteins specified by herpes simplex virus. VI. Viral proteins in the plasma membrane.

Authors:  J W Heine; P G Spear; B Roizman
Journal:  J Virol       Date:  1972-03       Impact factor: 5.103

7.  Antigenic differences between isolates of herpesvirus type 2.

Authors:  P Seth; W E Rawls; R Duff; F Rapp; E Adam; J L Melnick
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

8.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

9.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

10.  Proteins specified by herpes simplex virus. XIII. Glycosylation of viral polypeptides.

Authors:  R W Honess; B Roizman
Journal:  J Virol       Date:  1975-11       Impact factor: 5.103

View more
  32 in total

1.  Characterization of the gene encoding herpes simplex virus type 2 glycoprotein C and comparison with the type 1 counterpart.

Authors:  M A Swain; R W Peet; D A Galloway
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

2.  Detection by monoclonal antibodies of an early membrane protein induced by Epstein-Barr virus.

Authors:  N Balachandran; J Pittari; L M Hutt-Fletcher
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

3.  Differences in antigenic properties of Fc-binding activity during infection with herpes simplex virus type 1.

Authors:  S Welling-Wester; J Vos; J B Wilterdink
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

Review 4.  Monoclonal antibodies against microorganisms.

Authors:  R A Polin
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

5.  Mapping of a herpes simplex virus type 2-encoded function that affects the susceptibility of herpes simplex virus-infected target cells to lysis by herpes simplex virus-specific cytotoxic T lymphocytes.

Authors:  V C Carter; S R Jennings; P L Rice; S S Tevethia
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus.

Authors:  R L Ashley; L Corey
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

7.  Mapping of the structural gene for the herpes simplex virus type 2 counterpart of herpes simplex virus type 1 glycoprotein C and identification of a type 2 mutant which does not express this glycoprotein.

Authors:  K M Zezulak; P G Spear
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

8.  Antibodies to a synthetic oligopeptide that react with herpes simplex virus type 1 and 2 glycoprotein C.

Authors:  M Zweig; S D Showalter; D J Simms; B Hampar
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

9.  Glycoproteins of herpes simplex virus type 2 as defined by monoclonal antibodies.

Authors:  N Balachandran; D Harnish; W E Rawls; S Bacchetti
Journal:  J Virol       Date:  1982-10       Impact factor: 5.103

10.  Monoclonal antibodies against three major glycoproteins of varicella-zoster virus.

Authors:  C Grose; D P Edwards; W E Friedrichs; K A Weigle; W L McGuire
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.